Novo Nordisk A/S (NOVO-B)の価格はいくらですか

Novo Nordisk A/S (NOVO-B)の価格は$47.55です

Novo Nordisk A/S (NOVO-B)の時価総額は何ですか

Novo Nordisk A/S (NOVO-B)の時価総額は$211.25Bです

Novo Nordisk A/S (NOVO-B) の利益

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

年	利益	変化
提供された日付のデータは十分ではありません。

年

利益

変化

提供された日付のデータは十分ではありません。

企業	利益	利益の差	国
Eli Lilly and Company LLY.US	$33.59B	63.83%	US
Johnson & Johnson JNJ.US	$25.20B	22.88%	US
AbbVie Inc. ABBV.US	$8.70B	-57.58%	US
Roche Holding AG RO.SW	$21.39B	4.31%	CH
Merck & Co., Inc. MRK.US	$5.95B	-70.99%	US

企業

利益

利益の差

国